BridgeBio Q3 revenue rises to $353.2 million as Attruby sales climb

BridgeBio Pharma, Inc. (BBIO) reported third-quarter 2026 total revenues, net of $353.2 million, up from $120.7 million a year earlier, the company said in a filing furnished under Item 2.02 on Oct. 29. The company describes itself as a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions.

Shares were little changed in after-hours trading as of 4:37 p.m. ET, from a regular-session close of $70.75.

Here's how the company did:

• Total revenues, net: $353.2 million vs. $120.7 million a year earlier
• Net product revenue: $253.3 million vs. $108.1 million a year earlier
• Loss from operations: $11.6 million vs. $145.2 million a year earlier
• Net loss per share: 42 cents vs. 95 cents a year earlier
• Net loss attributable to common stockholders: $83.0 million vs. $182.7 million a year earlier

The company said U.S. Attruby net product revenue was $253.2 million, with $0.1 million from Rest of World. Royalty revenue was $20.5 million, and license and services revenue was $79.3 million.

License and services revenue included a $75.0 million sales milestone under the Bayer License Agreement, achieved during the quarter.

Revenue drivers

U.S. Attruby net product revenue rose $145.2 million from a year earlier, the company said.

Revenue has risen in each of the last three quarters, from $120.7 million in the third quarter of 2025 to $243.7 million in the second quarter of 2026, according to its SEC filings.

Chief Executive Officer Neil Kumar said, "I'm heartened by how consistently the evidence for acoramidis keeps pointing in the same direction." He added that the company had added two more large real-world comparisons during the quarter.

Regulatory dates

BBP-418 for LGMD2I/R9 has a Nov. 27, 2026 PDUFA date, with Priority Review. The company said its Neuromuscular Account Managers have reached more than 70% of MDA centers and expect to reach at least 90% by the PDUFA date.

Oral infigratinib for achondroplasia has a Feb. 4, 2027 PDUFA date, with Priority Review.

Encaleret for ADH1 has a May 8, 2027 PDUFA date, with Priority Review.

Chief Commercial Officer Matt Outten said, "Our field teams for all three programs are hired and ready to serve these communities from day one."

Costs and cash

Total operating costs and expenses were $364.8 million, compared with $265.9 million a year earlier. Selling, general and administrative expenses rose $63.2 million, and research and development expenses rose $30.6 million.

Net loss attributable to common stockholders included $26.3 million of preferred stock dividends and accretion, the filing shows.

Cash, cash equivalents and marketable securities totaled $1.5 billion as of Sept. 30, 2026, up from $587.5 million on Dec. 31, 2025.